3,5-dinitro-4-chloro-alpha,alpha,alpha-trifluorotoluene: affects mitochondria isolated from rat liver; RN given refers to unlabeled cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 9809 |
| CHEMBL ID | 144530 |
| SCHEMBL ID | 455937 |
| MeSH ID | M0088447 |
| Synonym |
|---|
| 1-chloro-2,6-dinitro-4-(trifluoromethyl)benzene |
| 4-chloro-.alpha.,.alpha.-trifluoro-3,5-dinitrotoluene |
| 393-75-9 |
| 4-chloro-3,5-dinitrobenzotrifluoride |
| 2-chloro-1,3-dinitro-5-(trifluoromethyl)benzene |
| nsc88274 |
| benzene,3-dinitro-5-(trifluoromethyl)- |
| toluene,.alpha.,.alpha.-trifluoro-3,5-dinitro- |
| trifluoromethyl-3,5-dinitro-4-chlorobenzene |
| nsc-88274 |
| 4-chloro-3,.alpha.,.alpha.-trifluorotoluene |
| 3,5-dinitro-4-chlorobenzotrifluoride |
| 4-(trifluoromethyl)-2,6-dinitrochlorobenzene |
| 2,6-dinitro-4-trifluoromethylchlorobenzene |
| benzene, 2-chloro-5-(trifluoromethyl)-1,3-dinitro- |
| benzene, 2-chloro-1,3-dinitro-5-(trifluoromethyl)- |
| benzotrifluoride, 4-chloro-3,5-dinitro- |
| nsc 88274 |
| toluene, 4-chloro-alpha,alpha,alpha-trifluoro-3,5-dinitro- |
| 4-chloro-3,5-dinitro-alpha,alpha,alpha-trifluorotoluene |
| hsdb 4262 |
| 4-chloro-alpha,alpha,alpha-trifluoro-3,5-dinitrotoluene |
| ccris 2818 |
| toluene, 4-chloro-3,5-dinitro-alpha,alpha,alpha-trifluoro- |
| einecs 206-889-3 |
| brn 1220937 |
| 3,5-dinitro-4-chloro-alpha,alpha,alpha-trifluorotoluene |
| cdnt |
| NCGC00091329-01 |
| 4-chloro-3,5-dinitro-a,a,a-trifluorotoluene |
| 4-chloro-3,5-dinitrobenzotrifluoride, 98% |
| NCIOPEN2_005439 |
| AC-10850 |
| chloralin |
| CHEMBL144530 , |
| bdbm50068343 |
| 2-chloro-1,3-dinitro-5-trifluoromethyl-benzene |
| AKOS000120597 |
| NCGC00091329-02 |
| NCGC00091329-03 |
| dtxsid8024781 , |
| dtxcid604781 |
| cas-393-75-9 |
| tox21_200966 |
| NCGC00258519-01 |
| dnt-cl |
| ec 206-889-3 |
| t97iub50mn , |
| unii-t97iub50mn |
| FT-0601466 |
| STL371257 |
| toluene, 4-chloro-.alpha.,.alpha.,.alpha.-trifluoro-3,5-dinitro- |
| 4-chloro-3,5-dinitro-.alpha.,.alpha.,.alpha.-trifluorotoluene |
| 1,3-dinitro-2-chloro-5-(trifluoromethyl)benzene |
| 4-chloro-3,5-dinitrobenzotrifluoride [hsdb] |
| 4-chloro-.alpha.,.alpha.,.alpha.-trifluoro-3,5-dinitrotoluene |
| SCHEMBL455937 |
| BBL027633 |
| 2-chloro-1,3-dinitro-5-trifluoromethylbenzene |
| 2-chloro-5-trifluoromethyl-1,3-dinitrobenzene |
| 4-chloro-3,5-dinitro benzotrifluoride |
| 2,6-dinitro-4-trifluoromethyl-1-chlorobenzene |
| 1-trifluoromethyl-3,5-dinitro-4-chlorobenzene |
| 4-chloro-3,5-dinitro-benzotrifluoride |
| 4-chloro-3, 5-dinitrobenzotrifluoride |
| 3,5-dinitro-4-chloro-.alpha.,.alpha.,.alpha.-trifluorotoluene |
| toluene, 4-chloro-3,5-dinitro-.alpha.,.alpha.,.alpha.-trifluoro- |
| benzene, 1-chloro-2,6-dinitro-4-trifluoromethyl |
| W-106439 |
| mfcd00007068 |
| Q15632822 |
| EN300-16698 |
| AMY8775 |
| CS-W012376 |
| Z56755842 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 31.6228 | 0.0040 | 23.8416 | 100.0000 | AID485290 |
| Chain A, Cruzipain | Trypanosoma cruzi | Potency | 3.9811 | 0.0020 | 14.6779 | 39.8107 | AID1476 |
| acetylcholinesterase | Homo sapiens (human) | Potency | 71.3274 | 0.0025 | 41.7960 | 15,848.9004 | AID1347395; AID1347399 |
| 15-lipoxygenase, partial | Homo sapiens (human) | Potency | 12.5893 | 0.0126 | 10.6917 | 88.5700 | AID887 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 22.8973 | 0.0007 | 14.5928 | 83.7951 | AID1259369; AID1259392 |
| AR protein | Homo sapiens (human) | Potency | 13.3512 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247; AID1259381; AID743040 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 19.9526 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) | Homo sapiens (human) | Potency | 79.4328 | 0.0013 | 7.7625 | 44.6684 | AID2120 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 5.0119 | 0.0013 | 18.0743 | 39.8107 | AID926; AID938 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 41.6357 | 0.0006 | 57.9133 | 22,387.1992 | AID1259377; AID1259378 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 54.7044 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224893 |
| progesterone receptor | Homo sapiens (human) | Potency | 21.7782 | 0.0004 | 17.9460 | 75.1148 | AID1346795 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 6.9488 | 0.0008 | 17.5051 | 59.3239 | AID1159531 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 61.3793 | 0.0015 | 30.6073 | 15,848.9004 | AID1224848; AID1224849; AID1259403 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 27.4171 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 60.1993 | 0.0002 | 29.3054 | 16,493.5996 | AID743069; AID743078 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 33.3212 | 0.0010 | 19.4141 | 70.9645 | AID588537; AID743094 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 12.3570 | 0.0237 | 23.2282 | 63.5986 | AID743223 |
| 15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 10.0000 | 0.0018 | 15.6638 | 39.8107 | AID894 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 19.9848 | 0.0006 | 27.2152 | 1,122.0200 | AID743202; AID743219 |
| cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 25.1189 | 0.0316 | 10.2792 | 39.8107 | AID884; AID885 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Nuclear receptor ROR-gamma | Homo sapiens (human) | Potency | 26.6032 | 0.0266 | 22.4482 | 66.8242 | AID651802 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Thioredoxin reductase 2 | Plasmodium falciparum 3D7 | IC50 (µMol) | 8.0000 | 8.0000 | 8.0000 | 8.0000 | AID263780 |
| Thioredoxin reductase 1, cytoplasmic | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.0432 | 2.2655 | 5.0000 | AID263781 |
| Thioredoxin reductase 3 | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.3500 | 3.1167 | 5.0000 | AID263781 |
| Thioredoxin reductase 2, mitochondrial | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.3500 | 3.1167 | 5.0000 | AID263781 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID100752 | Compound was evaluated in vitro against Leishmania donovani parasite | 1998 | Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24 | Synthesis and biological evaluation of 4-chloro-3, 5-dinitrobenzotrifluoride analogues as antileishmanial agents. |
| AID19658 | Partition coefficient (logP) | 1998 | Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24 | Synthesis and biological evaluation of 4-chloro-3, 5-dinitrobenzotrifluoride analogues as antileishmanial agents. |
| AID87106 | % suppression of parasitaemia was measured in vivo against Visceral Leishmania donovani in hamsters at 208 mg/kg of dosage level. | 1998 | Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24 | Synthesis and biological evaluation of 4-chloro-3, 5-dinitrobenzotrifluoride analogues as antileishmanial agents. |
| AID263781 | Inhibition of human TrxR | 2006 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8 | Specific inhibitors of Plasmodium falciparum thioredoxin reductase as potential antimalarial agents. |
| AID87107 | % suppression of parasitaemia was measured in vivo against Visceral Leishmania donovani in hamsters at 52 mg/kg of dosage level. | 1998 | Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24 | Synthesis and biological evaluation of 4-chloro-3, 5-dinitrobenzotrifluoride analogues as antileishmanial agents. |
| AID263780 | Inhibition of Plasmodium falciparum TrxR | 2006 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8 | Specific inhibitors of Plasmodium falciparum thioredoxin reductase as potential antimalarial agents. |
| AID263782 | Selectivity for Plasmodium falciparum TrxR over human TrxR | 2006 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8 | Specific inhibitors of Plasmodium falciparum thioredoxin reductase as potential antimalarial agents. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 5 (26.32) | 18.7374 |
| 1990's | 2 (10.53) | 18.2507 |
| 2000's | 8 (42.11) | 29.6817 |
| 2010's | 3 (15.79) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.76) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (5.26%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 18 (94.74%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||